Effect of telavancin (vibativ) on routine coagulation test results

Robert Gosselin, William Dager, Aaron Roberts, Leslie Freeman, Lisa Gandy, Jeffrey Gregg, Denis M Dwyre

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Telavancin (Vibativ, Astellas Pharma US, Deerfield, IL) is a lipoglycopeptide antibiotic that has activity against gram-positive microorganisms, but also has the ability to bind to artificial phospholipids found in coagulation reagents. Normal pooled plasma was spiked with telavancin to obtain concentrations of 0, 12.5, 25, 50, 75, 100, 125, and 150 μg/mL of drug. Samples were tested using 3 different prothrombin time/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) reagent systems, as well as for fibrinogen level, thrombin time, D-dimer level, dilute Russell viper venom time (DRVVT), protein C activity, and protein S activity. There was no effect of telavancin seen with non-phospholipid-dependent assays: fibrinogen level, thrombin time, and D-dimer testing. All INR and aPTT systems demonstrated concentration-dependent increases in clotting times, with Innovin (Siemens Healthcare Diagnostics, Deerfield, IL) INRs the most dramatic. False-positive DRVVT ratios started at 12.5 μg/mL of telavancin, with no effect on protein C or protein S levels until the telavancin level reached more than 100 μg/mL.

Original languageEnglish (US)
Pages (from-to)848-854
Number of pages7
JournalAmerican Journal of Clinical Pathology
Issue number6
StatePublished - Dec 2011


  • Activated partial thromboplastin time
  • aPTT
  • Coagulation tests
  • INR
  • International normalized ratio
  • Telavancin

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Effect of telavancin (vibativ) on routine coagulation test results'. Together they form a unique fingerprint.

Cite this